Its role Owner
Moderna is a U.S.-based biotechnology company focused on the discovery, development, and manufacturing of messenger RNA (mRNA) therapeutics and vaccines. Headquartered in Cambridge, Massachusetts and founded in 2010, the company applies nucleic acid and delivery chemistry—particularly lipid nanoparticle (LNP) formulations—to encode proteins that can prevent or treat disease.
Moderna’s portfolio spans infectious diseases, oncology, rare diseases, cardiovascular and autoimmune disorders, supported by an integrated mRNA platform, in-house and partnered R&D, and clinical development programs. The company operates clinical and commercial manufacturing capabilities for mRNA drug substance and finished vaccines, including process development, scale-up, and quality systems. Moderna is publicly listed on Nasdaq under the ticker MRNA and is known for its COVID-19 vaccine (Spikevax), alongside a broader pipeline of investigational mRNA products.
chemXplore tracks 2 projects involving Moderna, of which one is active.
Besides this one, the record holds 1 completed project.
Closest to start-up first.
The 1 that is completed, on hold or cancelled are in the record. See all 2 in chemXplore →
First Phase 3 success for an individualized mRNA neoantigen therapy; trial met RFS and DMFS in completely resected stage IIB–IV melanoma; OS pending; safety consistent.
5-year Phase 2b follow-up: combination showed 49% RFS reduction (HR 0.51), 59% DMFS reduction (HR 0.411); OS trend (HR 0.471). Safety consistent; increased neoantigen-specific T‑cell clonotypes
Intismeran autogene with KEYTRUDA shows 49% reduced risk of recurrence or death in high-risk melanoma over five years. Further data to be presented at a future medical conference.
Séverine Lemoine will lead operations in France, focusing on product launches and expanding the local presence in oncology.
The new centre will focus on mRNA vaccine R&D and manufacturing, creating jobs and boosting the UK's life sciences sector. Construction starts in 2023, with operations expected by 2025.
NHS patients will access next-gen mRNA vaccines via a new UK facility, boosting pandemic response and job creation. The centre will enhance R&D and local manufacturing for various diseases.
active all projects
